Brent Warner

President, Gene Therapy

Mr. Warner joined Poseida as our President, Gene Therapy in February 2022, bringing significant biopharmaceutical experience in rare diseases and gene therapy. Most recently with Novartis as Vice President, Gene Therapy and Rare Disease, he was responsible for building a division to commercialize multiple gene therapies. His prior roles include serving as a U.S. commercial leader in Hemophilia A at BioMarin Pharmaceuticals, in a variety of strategic and operational roles at Biogen, and in commercial launch roles in blood disorders at Baxalta, now a wholly owned subsidiary of Takeda. Mr. Warner has an MBA with an emphasis in marketing and finance and a Bachelor of Business Administration degree, both from Northwood University in Michigan.